Quantitation of absolute numbers of EBV-specific and alloreactive T cells
. | Day 0 . | Day 7 . | Day 14 . | Day 21 . | Day 28 . |
---|---|---|---|---|---|
Donor A | |||||
Intracellular IFN-γ production* | |||||
Anti-EBV CD3+ | 700 | 3 100 | 15 600 | 13 500 | 23 100 |
Anti-allo CD3+ | 1 100 | 500 | 600 | 400 | 200 |
Anti-EBV CD3+CD8+ | 315 | 1 880 | 11 407 | 9 928 | 16 660 |
Anti-allo CD3+CD8+ | 495 | 564 | 366 | 204 | 136 |
Anti-EBV CD3+CD4+ | 80 | 810 | 2 520 | 4 536 | 5 848 |
Anti-allo CD3+CD4+ | ND | 54 | 42 | 72 | 170 |
Limiting-dilution analysis† | |||||
Anti-EBV CD3+ | 28 | 35 | 274 | 300 | 333 |
Anti-allo CD3+ | 36 | 6.6 | 4.1 | 1.4 | 0.9 |
Donor B | |||||
Intracellular IFN-γ production* | |||||
Anti-EBV CD3+ | 900 | 1 000 | 5 100 | 6 700 | 5 200 |
Anti-allo CD3+ | 600 | 400 | 200 | 100 | ND |
Anti-EBV CD3+CD8+ | 448 | 580 | 2 117 | 6 298 | 7 200 |
Anti-allo CD3+CD8+ | 288 | 435 | 232 | 67 | ND |
Anti-EBV CD3+CD4+ | 657 | 420 | 2 982 | 1 800 | 561 |
Anti-allo CD3+CD4+ | 365 | 70 | 71 | ND | ND |
Limiting-dilution analysis† | |||||
Anti-EBV CD3+ | 10 | 22 | 38 | 70 | 132 |
Anti-allo CD3+ | 8 | 23 | 3 | 1 | 0.8 |
. | Day 0 . | Day 7 . | Day 14 . | Day 21 . | Day 28 . |
---|---|---|---|---|---|
Donor A | |||||
Intracellular IFN-γ production* | |||||
Anti-EBV CD3+ | 700 | 3 100 | 15 600 | 13 500 | 23 100 |
Anti-allo CD3+ | 1 100 | 500 | 600 | 400 | 200 |
Anti-EBV CD3+CD8+ | 315 | 1 880 | 11 407 | 9 928 | 16 660 |
Anti-allo CD3+CD8+ | 495 | 564 | 366 | 204 | 136 |
Anti-EBV CD3+CD4+ | 80 | 810 | 2 520 | 4 536 | 5 848 |
Anti-allo CD3+CD4+ | ND | 54 | 42 | 72 | 170 |
Limiting-dilution analysis† | |||||
Anti-EBV CD3+ | 28 | 35 | 274 | 300 | 333 |
Anti-allo CD3+ | 36 | 6.6 | 4.1 | 1.4 | 0.9 |
Donor B | |||||
Intracellular IFN-γ production* | |||||
Anti-EBV CD3+ | 900 | 1 000 | 5 100 | 6 700 | 5 200 |
Anti-allo CD3+ | 600 | 400 | 200 | 100 | ND |
Anti-EBV CD3+CD8+ | 448 | 580 | 2 117 | 6 298 | 7 200 |
Anti-allo CD3+CD8+ | 288 | 435 | 232 | 67 | ND |
Anti-EBV CD3+CD4+ | 657 | 420 | 2 982 | 1 800 | 561 |
Anti-allo CD3+CD4+ | 365 | 70 | 71 | ND | ND |
Limiting-dilution analysis† | |||||
Anti-EBV CD3+ | 10 | 22 | 38 | 70 | 132 |
Anti-allo CD3+ | 8 | 23 | 3 | 1 | 0.8 |
Absolute numbers were determined per 105 T lymphocytes by LDA and intracellular IFN-γ production. EBV-specific and alloreactive CD3+ cells per 105 T lymphocytes were determined by LDA at weekly incremental time points from day 0 to day 28 during the generation of EBV-specific T-cell lines of donors A and B. Results were compared to EBV-specific and alloreactive CD3+ cells producing intracellular IFN-γ per 105 T lymphocytes. FACS analysis also determined the CD8+IFN-γ+ and CD4+IFN-γ+ subpopulations per 105T cells.
ND indicates not detectable.
Absolute numbers of EBV-specific and alloreactive T cells per 105 T lymphocytes by intracellular IFN-γ production.
Absolute numbers of EBV-specific and alloreactive T cells per 105 T lymphocytes obtained by LDA.